Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes: Two-Year Results From the Randomized, Placebo-Controlled Protégé Trial

Protégé was a phase 3, randomized, double-blind, parallel, placebo-controlled 2-year study of three intravenous teplizumab dosing regimens, administered daily for 14 days at baseline and again after 26 weeks, in new-onset type 1 diabetes. We sought to determine efficacy and safety of teplizumab immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagopian, William, Ferry, Robert J., Sherry, Nicole, Carlin, David, Bonvini, Ezio, Johnson, Syd, Stein, Kathryn E., Koenig, Scott, Daifotis, Anastasia G., Herold, Kevan C., Ludvigsson, Johnny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3806608/
https://www.ncbi.nlm.nih.gov/pubmed/23801579
http://dx.doi.org/10.2337/db13-0236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3806608/
https://www.ncbi.nlm.nih.gov/pubmed/23801579
http://dx.doi.org/10.2337/db13-0236

Ejemplares similares